Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)
| Autor: | Christopher P. Evans, Angelo J. Cambio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Common disease Pharmacological management Population Psychological intervention urologic and male genital diseases alpha blockers Quality of life medicine Pharmacology (medical) Oncology & Carcinogenesis General Pharmacology Toxicology and Pharmaceutics Intensive care medicine education Original Research Gynecology education.field_of_study Chemical Health and Safety Benign prostatic hyperplasia business.industry urogenital system General Medicine medicine.disease benign prostatic hypertrophy Clinical trial Natural history quality of life BPH Public Health and Health Services 5 alpha-reductase inhibitor Benign prostatic hyperplasia (BPH) business Safety Research |
| Zdroj: | Therapeutics and Clinical Risk Management Therapeutics and clinical risk management, vol 3, iss 1 |
| ISSN: | 1178-203X 1176-6336 |
| Popis: | Author(s): Cambio, Angelo J; Evans, Christopher P | Abstract: BackgroundBenign prostatic hyperplasia (BPH) is a common disease of the aging male population. BPH treatment includes a variety of pharmacological and surgical interventions. The goal of this paper is to review the natural history of BPH, outcomes of pharmacological management, effects on quality of life (QoL), future pharmacotherapies, and associated patient-focused perspectives.Materials and methodsMedline searches for the keywords benign prostatic hyperplasia, BPH, alpha blockers, 5 alpha-reductase, and quality of life were performed. Relevant literature was reviewed and analyzed.ResultsAlpha blockers, 5 alpha-reductase inhibitors, and phytotherapy are the three categories of pharmaceutical interventions currently available for BPH. Various clinical trials have shown that alpha blockers and 5 alpha-reductase inhibitors are safe, efficacious, and improve QoL in patients with BPH. The evidence for phytotherapeutics is not as convincing. The current armamentarium of pharmaceutical interventions are encompassed in these three classes of medications. New pharmacotherapies based on novel mechanisms are on the horizon.ConclusionThere are a variety of safe and efficacious medical therapies available for the management of BPH and it is important for the practicing physician to have an understanding of these pharmacotherapies and their potential impact on the patient. There is not enough evidence to make a recommendation regarding phytotherapy use. New classes of drugs for BPH will likely find their way into routine use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|